MedTrace Logo

ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

NCT02435927 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-04-28

No results posted yet for this study

Summary

This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.

Conditions

Interventions

DRUG

ASLAN001+ CAPOX (Oxaliplatin, capecitabine)

ASLAN001 in combination with oxaliplatin and capecitabine

DRUG

ASLAN001 + mFolfox6 (5-FU, leucovorin)

ASLAN001 in combination with 5-FU and leucovorin

Sponsors & Collaborators

  • ASLAN Pharmaceuticals

    collaborator OTHER

  • National Medical Research Council (NMRC), Singapore

    collaborator OTHER_GOV

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Matthew CH Ng · National Cancer Centre, Singapore

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02435927 on ClinicalTrials.gov